Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label phase II study, with the aim of investigating the efficacy and safety
of Tislelizumab + Fruquintinib combination therapy in ARID1A-mutated pMMR/MSS metastatic
colorectal cancer whose tumor progressed after two or more lines of chemotherapy. Patients
with hypermutated CRC that carries POLE/POLD1 mutations cannot be included.